Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRL1 | P41146 | 15/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL739328 | 0.92 | CYP2C9 (0.39) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL742231 | 0.92 | CYP2C9 (0.39) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL10043090 | 0.91 | OPRL1 (0.41) | OPRL1CYP2C9MAPTGAAALDH1A1 | |
| SCHEMBL10043092 | 0.90 | OPRL1 (0.41) | OPRL1CYP2C9MAPTGAAALDH1A1 | |
| SCHEMBL729388 | 0.89 | OPRL1 (0.36) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL12975822 | 0.89 | CYP2C9 (0.41) | OPRL1CYP2C9MAPTALDH1A1LMNA | |
| SCHEMBL11959294 | 0.89 | CYP2C9 (0.41) | OPRL1CYP2C9MAPTGAAALDH1A1 | |
| SCHEMBL21321650 | 0.89 | CYP2C9 (0.41) | OPRL1CYP2C9MAPTGAAALDH1A1 | |
| SCHEMBL10043085 | 0.89 | CYP2C9 (0.41) | OPRL1CYP2C9MAPTGAAALDH1A1 | |
| SCHEMBL16789606 | 0.89 | CYP2C9 (0.41) | OPRL1CYP2C9MAPTGAAALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2279990-B1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | JNC CORP (JP) | 2016-10-26 | — | — | EP | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-8137583-B2 | Liquid crystal four-ring compound having fluorine, liquid crystal composition, and liquid crystal display device | JNC CORPORATION (JP) | 2012-03-20 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | CHISSO CORPORATION | 2011-04-07 | — | — | US | disclosed |
| EP-2279990-A1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2011-02-02 | — | — | EP | disclosed |
| EP-2279990-A1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | Chisso Corporation (JP) | 2011-02-02 | — | — | EP | disclosed |
| WO-2009145101-A1 | LIQUID CRYSTALLINE TETRACYCLIC COMPOUND HAVING FLUORINE ATOM, LIQUID CRYSTAL COMPOSITION AND LIQUID CRYSTAL DISPLAY ELEMENT | チッソ株式会社 (JP) | 2009-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110079753-A1 | LIQUID CRYSTAL FOUR-RING COMPOUND HAVING FLUORINE, LIQUID CRYSTAL COMPOSITION, AND LIQUID CRYSTAL DISPLAY DEVICE | ROCK1, ROCK2, LEF1 | OPRL1 3448/4885CYP2C9 2320/4885MAPT 1215/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.